NCT02004093 - A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer | Biotech Hunter

Enrollment

149

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Ovarian Cancer

Interventions

DRUG

pertuzumab

Loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks

DRUG

paclitaxel

175 mg/m2 IV every 3 weeks for 6 cycles

DRUG

gemcitabine

1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles

DRUG

carboplatin

Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles

Trial Locations (34)

1000

Brussels

1122

Budapest

2610

Wilrijk

3000

Leuven

4032

Debrecen

9024

Győr

20133

Milan

28041

Madrid

43100

Parma

46009

Valencia

105203

Moscow

115478

Moscow

117837

Moscow

125284

Moscow

143423

Moscow

197022

Saint Petersburg

197758

Saint Petersburg

420029

Kazan'

634028

Tomsk

T2N 4N2

Calgary

V1Y 5L3

Kelowna

V5Z 4E6

Vancouver

1066 CX

Amsterdam

1081 HV

Amsterdam

60-535

Poznan

02-781

Warsaw

08035

Barcelona

08036

Barcelona

B18 7QH

Birmingham

W12 OHS

London

M20 4BX

Manchester

PL6 8DH

Plymouth

SM2 5PT

Sutton

BA21 4AT

Yeovil

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY